Literature DB >> 32920733

Tumor necrosis by pretreatment breast MRI: association with neoadjuvant systemic therapy (NAST) response in triple-negative breast cancer (TNBC).

Abeer H Abdelhafez1, Benjamin C Musall2, Wei T Yang1, Gaiane M Rauch3,4, Beatriz E Adrada1, KennethR Hess5, Jong Bum Son2, Ken-Pin Hwang2, Rosalind P Candelaria1, Lumarie Santiago1, Gary J Whitman1, Huong T Le-Petross1, Tanya W Moseley1, Elsa Arribas1, Deanna L Lane1, Marion E Scoggins1, Jessica W T Leung1, Hagar S Mahmoud1, Jason B White6, Elizabeth E Ravenberg6, Jennifer K Litton6, Vicente Valero6, Peng Wei5, Alastair M Thompson7, Stacy L Moulder6, Mark D Pagel2,8, Jingfei Ma2.   

Abstract

PURPOSE: To determine if tumor necrosis by pretreatment breast MRI and its quantitative imaging characteristics are associated with response to NAST in TNBC.
METHODS: This retrospective study included 85 TNBC patients (mean age 51.8 ± 13 years) with MRI before NAST and definitive surgery during 2010-2018. Each MRI included T2-weighted, diffusion-weighted (DWI), and dynamic contrast-enhanced (DCE) imaging. For each index carcinoma, total tumor volume including necrosis (TTV), excluding necrosis (TV), and the necrosis-only volume (NV) were segmented on early-phase DCE subtractions and DWI images. NV and %NV were calculated. Percent enhancement on early and late phases of DCE and apparent diffusion coefficient were extracted from TTV, TV, and NV. Association between necrosis with pathological complete response (pCR) was assessed using odds ratio (OR). Multivariable analysis was used to evaluate the prognostic value of necrosis with T stage and nodal status at staging. Mann-Whitney U tests and area under the curve (AUC) were used to assess performance of imaging metrics for discriminating pCR vs non-pCR.
RESULTS: Of 39 patients (46%) with necrosis, 17 had pCR and 22 did not. Necrosis was not associated with pCR (OR, 0.995; 95% confidence interval [CI] 0.4-2.3) and was not an independent prognostic factor when combined with T stage and nodal status at staging (P = 0.46). None of the imaging metrics differed significantly between pCR and non-pCR in patients with necrosis (AUC < 0.6 and P > 0.40).
CONCLUSION: No significant association was found between necrosis by pretreatment MRI or the quantitative imaging characteristics of tumor necrosis and response to NAST in TNBC.

Entities:  

Keywords:  Diffusion-weighted MRI; Multiparametric MRI; Necrosis; Neoadjuvant therapy; Triple-negative breast cancer

Mesh:

Substances:

Year:  2020        PMID: 32920733      PMCID: PMC8294182          DOI: 10.1007/s10549-020-05917-7

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  32 in total

1.  Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy.

Authors:  Nehmat Houssami; Petra Macaskill; Gunter von Minckwitz; Michael L Marinovich; Eleftherios Mamounas
Journal:  Eur J Cancer       Date:  2012-07-03       Impact factor: 9.162

2.  The necrosis sign in magnetic resonance-mammography: diagnostic accuracy in 1,084 histologically verified breast lesions.

Authors:  Matthias Dietzel; Pascal A T Baltzer; Tibor Vag; Aimee Herzog; Mieczyslaw Gajda; Oumar Camara; Werner A Kaiser
Journal:  Breast J       Date:  2010 Nov-Dec       Impact factor: 2.431

3.  Review of Triple Negative Breast Cancer and the Impact of Inducible Nitric Oxide Synthase on Tumor Biology and Patient Outcomes.

Authors:  Elaine M Walsh; Maccon M Keane; David A Wink; Grace Callagy; Sharon A Glynn
Journal:  Crit Rev Oncog       Date:  2016

Review 4.  Neoadjuvant chemotherapy in breast cancers.

Authors:  Shahla Masood
Journal:  Womens Health (Lond)       Date:  2016-09

5.  Prognostic factors in early-stage triple-negative breast cancer: lessons and limits from clinical practice.

Authors:  Mirco Pistelli; Alessandra Pagliacci; Nicola Battelli; Alfredo Santinelli; Tommasina Biscotti; Zelmira Ballatore; Rossana Berardi; Stefano Cascinu
Journal:  Anticancer Res       Date:  2013-06       Impact factor: 2.480

6.  Pretreatment MR Imaging Features of Triple-Negative Breast Cancer: Association with Response to Neoadjuvant Chemotherapy and Recurrence-Free Survival.

Authors:  Min Sun Bae; Sung Ui Shin; Han Suk Ryu; Wonshik Han; Seock-Ah Im; In-Ae Park; Dong-Young Noh; Woo Kyung Moon
Journal:  Radiology       Date:  2016-05-19       Impact factor: 11.105

7.  Clinical significance of morphologic characteristics in triple negative breast cancer.

Authors:  Dong Won Ryu; Min Jung Jung; Woo Sik Choi; Chung Han Lee
Journal:  J Korean Surg Soc       Date:  2011-05-06

Review 8.  Tumor necrosis as a prognostic variable for the clinical outcome in patients with renal cell carcinoma: a systematic review and meta-analysis.

Authors:  Lijin Zhang; Zhenlei Zha; Wei Qu; Hu Zhao; Jun Yuan; Yejun Feng; Bin Wu
Journal:  BMC Cancer       Date:  2018-09-03       Impact factor: 4.430

9.  Attempt towards a novel classification of triple-negative breast cancer using immunohistochemical markers.

Authors:  Yan-Xi Liu; Ke-Ren Wang; Hua Xing; Xu-Jie Zhai; Li-Ping Wang; Wan Wang
Journal:  Oncol Lett       Date:  2016-06-23       Impact factor: 2.967

10.  Clinical impact and network of determinants of tumour necrosis in colorectal cancer.

Authors:  Sara A Väyrynen; Juha P Väyrynen; Kai Klintrup; Jyrki Mäkelä; Tuomo J Karttunen; Anne Tuomisto; Markus J Mäkinen
Journal:  Br J Cancer       Date:  2016-05-19       Impact factor: 7.640

View more
  4 in total

1.  Cystic degeneration during neo-adjuvant chemotherapy predicts squamous metaplasia of triple negative breast cancer: report of two cases.

Authors:  Masayuki Inoue; Ayako Kimura; Tomomi Oka; Aya Yajima; Yudai Higuchi; Tatsuki Endo; Hideki Watanabe; Hiroshi Nakagomi; Toshio Oyama
Journal:  Int Cancer Conf J       Date:  2022-06-17

2.  Development and validation of a nomogram based on pretreatment dynamic contrast-enhanced MRI for the prediction of pathologic response after neoadjuvant chemotherapy for triple-negative breast cancer.

Authors:  Yanbo Li; Yongzi Chen; Rui Zhao; Yu Ji; Junnan Li; Ying Zhang; Hong Lu
Journal:  Eur Radiol       Date:  2021-11-12       Impact factor: 7.034

3.  Habitat Analysis of Breast Cancer-Enhanced MRI Reflects BRCA1 Mutation Determined by Immunohistochemistry.

Authors:  Tianming Du; Haidong Zhao
Journal:  Biomed Res Int       Date:  2022-03-30       Impact factor: 3.411

4.  Deep learning-based automatic segmentation for size and volumetric measurement of breast cancer on magnetic resonance imaging.

Authors:  Wenyi Yue; Hongtao Zhang; Juan Zhou; Guang Li; Zhe Tang; Zeyu Sun; Jianming Cai; Ning Tian; Shen Gao; Jinghui Dong; Yuan Liu; Xu Bai; Fugeng Sheng
Journal:  Front Oncol       Date:  2022-08-11       Impact factor: 5.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.